# Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy for patients with advanced cancer: protocol for a multi-method feasibility trial

**Authors:** Candice Richardson, Cindy Chan, Emily Macgregor, Crystal Hare, Breffni Hannon, SarahRose Black, Evan Schneider, Daniel Buchman, Stella Wang, Valeria Rac, Lusine Abrahamyan, Ella Huszti, Rinat Nissim, Madeline Li, Camilla Zimmermann, Emma Hapke, Daniel Rosenbaum, Sarah Hales

PMC · DOI: 10.1186/s40814-025-01706-5 · Pilot and Feasibility Studies · 2025-10-28

## TL;DR

This study tests a new therapy combining psilocybin and psychotherapy to help patients with advanced cancer manage distress.

## Contribution

Introduces PEARL therapy, a novel approach integrating psilocybin with evidence-based psychotherapies for advanced cancer patients.

## Key findings

- PEARL therapy will be evaluated for acceptability, feasibility, and safety in a small group of patients.
- Qualitative and quantitative data will be collected to assess outcomes and guide future research and policy.
- The study aims to inform clinical guidelines and therapist training for psychedelic-assisted therapies.

## Abstract

Individuals with advanced cancer often experience high levels of distress for which there are few standardized treatment approaches. Our multidisciplinary team has combined existing evidence-based approaches into Psilocybin-assisted Existential, Attachment, and RelationaL (PEARL) therapy. PEARL therapy combines elements from psilocybin-assisted psychotherapy, including preparatory therapy sessions, a high-dose psilocybin session, and integration sessions, with important elements from evidence-based psychotherapies designed for patients with advanced cancer.

This open-label, single-arm clinical trial will assess the acceptability, feasibility, and safety of PEARL therapy among 15 patients with advanced cancer, using qualitative and quantitative methodologies. Participants will complete self-report questionnaires at four time points pre- and post-intervention, as well as a qualitative interview one month after PEARL completion. Feasibility will be evaluated in terms of recruitment, retention, and adherence rates, while safety will be assessed based on the number of participants experiencing no serious adverse events.

This study will yield important information about the acceptability and feasibility of PEARL therapy and contribute to growing research around the efficacy of psychedelic-assisted therapies. PEARL therapy has the potential to improve quality of life among those with advanced disease, and careful research is needed to guide public policy, legislation, therapist training, and clinical guidelines.

NCT06416085; 2024–07-16.

The online version contains supplementary material available at 10.1186/s40814-025-01706-5.

## Linked entities

- **Chemicals:** psilocybin (PubChem CID 10624)
- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Diseases:** cancer (MESH:D009369)
- **Chemicals:** Psilocybin (MESH:D011562)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12570686/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12570686/full.md

## References

6 references — full list in the complete paper: https://tomesphere.com/paper/PMC12570686/full.md

---
Source: https://tomesphere.com/paper/PMC12570686